Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sramek

Showing results (21-30 of 156) with videos related to

Pageof 16
Sort By:
Alzheimer Disease and Associated Disorders|July 3, 1998
Guidelines for conducting bridging studies in Alzheimer diseaseN R Cutler, J J Sramek
European Journal of Clinical Pharmacology|January 1, 1995
Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging studyN R Cutler, J J Sramek
Archives of Biochemistry and Biophysics|May 1, 1977
Steady state kinetic mechanism of the Escherichia coli coenzyme A transferaseS J Sramek, F E Frerman
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 15, 2003
Galantamine hydrobromide: an agent for Alzheimer's diseaseVictoria Zarotsky, John J Sramek, Neal R Cutler
Drugs|July 12, 2002
Generalised anxiety disorder: treatment optionsJohn J Sramek, Victoria Zarotsky, Neal R Cutler
Hospital Formulary|February 9, 1988
Impact of removing oral neuroleptic liquids from the formulary of a large psychiatric hospitalC Jewett, J Sramek, G Itow, et al.
Journal of Clinical Psychopharmacology|November 19, 2003
The effect of antipsychotics on plasma lipidsJohn J Sramek, Neal R Cutler, Thomas Shiovitz
Drug Intelligence & Clinical Pharmacy|March 1, 1981
Psychotic exacerbation with haloperidolF L Tornatore, D Lee, J J Sramek
Drug Intelligence & Clinical Pharmacy|May 1, 1988
Neuroleptic plasma concentrations and clinical response: in search of a therapeutic windowJ J Sramek, S G Potkin, R Hahn
The Mount Sinai Journal of Medicine, New York|October 1, 1996
Neuroleptic dosing in Hispanic and Asian Inpatients with schizophreniaY Collazo, R Tam, J Sramek, et al.
Pageof 16

Showing results (21-30 of 156) with videos related to

Sort By:
Pageof 16
Alzheimer Disease and Associated Disorders|July 3, 1998
Guidelines for conducting bridging studies in Alzheimer diseaseN R Cutler, J J Sramek
European Journal of Clinical Pharmacology|January 1, 1995
Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging studyN R Cutler, J J Sramek
Archives of Biochemistry and Biophysics|May 1, 1977
Steady state kinetic mechanism of the Escherichia coli coenzyme A transferaseS J Sramek, F E Frerman
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 15, 2003
Galantamine hydrobromide: an agent for Alzheimer's diseaseVictoria Zarotsky, John J Sramek, Neal R Cutler
Drugs|July 12, 2002
Generalised anxiety disorder: treatment optionsJohn J Sramek, Victoria Zarotsky, Neal R Cutler
Hospital Formulary|February 9, 1988
Impact of removing oral neuroleptic liquids from the formulary of a large psychiatric hospitalC Jewett, J Sramek, G Itow, et al.
Journal of Clinical Psychopharmacology|November 19, 2003
The effect of antipsychotics on plasma lipidsJohn J Sramek, Neal R Cutler, Thomas Shiovitz
Drug Intelligence & Clinical Pharmacy|March 1, 1981
Psychotic exacerbation with haloperidolF L Tornatore, D Lee, J J Sramek
Drug Intelligence & Clinical Pharmacy|May 1, 1988
Neuroleptic plasma concentrations and clinical response: in search of a therapeutic windowJ J Sramek, S G Potkin, R Hahn
The Mount Sinai Journal of Medicine, New York|October 1, 1996
Neuroleptic dosing in Hispanic and Asian Inpatients with schizophreniaY Collazo, R Tam, J Sramek, et al.
Pageof 16